A global meta-analysis of particulate and gaseous air pollutants in relation to COVID-19 mortality and hospitalization
Abstract
A growing body of evidence implicates ambient air pollution in the exacerbation of clinical outcomes after SARS-CoV-2 infection. To synthesize this evidence, we performed a global systematic review and meta-analysis to precisely quantify the associations between exposure to specific atmospheric contaminants and the subsequent risks of COVID-19-related mortality and hospital admission.
Our methodology adhered to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) framework, involving a comprehensive search of scientific databases for literature published until the end of August 2025. From this search, 44 publications were deemed eligible for inclusion. We employed random-effects models to compute summary Risk Ratios (RRs) representing the change in health risk per 1 µg/m³ increment in atmospheric pollutant concentration. Our findings indicate that long term exposure to fine Particulate Matter (PM2.5), coarse Particles (PM₁₀), Nitrogen dioxide (NO₂), and Sulfur dioxide (SO₂) significantly increased the likelihood of fatal outcomes from COVID-19. The respective pooled RRs were 1.046 (95% CI: 1.031–1.062), 1.079 (95% CI: 1.005–1.154), 1.017 (95% CI: 1.004–1.029), and 1.077 (95% CI: 1.021– 1.133). Acute exposures to ambient PM2.5 and NO₂ concentrations were similarly associated with increased mortality, demonstrating risk ratios of
1.043 (95% CI: 1.033–1.053) and 1.033 (95% CI: 1.019–1.048) respectively per 1 µg/m³ increment. Additionally, both acute and chronic exposures to PM2.5, PM₁₀, and NO₂ showed significant associations with higher COVID-19 hospitalization rates.
This meta-analysis provides robust quantitative suggestion that ambient PM2.5, PM10, NO₂, and SO₂ are significant and modifiable risk factors for severe COVID-19 outcomes. These results emphasize the critical need for enhanced air quality standards as a fundamental element of public health policy to alleviate the impact of COVID-19 and bolster defenses against forthcoming respiratory epidemics.